C2i Genomics

C2i Genomics is a U.S.-based developer of personalized liquid biopsy technology. The company's liquid biopsy technology enables personalized testing of patients' tumors, identifying the "mutational fingerprint" unique to each patient. This genome-wide detection technology has the potential to perform ultra-sensitive quantitative analysis of circulating tumor DNA in patients' blood, precisely capturing the tumor's response to treatment.